See Phan
About
See Phan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, See Phan has authored 22 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in See Phan's work include Lung Cancer Treatments and Mutations (13 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Lung Cancer Research Studies (8 papers). See Phan is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Lung Cancer Research Studies (8 papers). See Phan collaborates with scholars based in United States, Spain and United Kingdom. See Phan's co-authors include Tony Mok, David S. Shames, Mark L. McCleland, Dustin Smith, Francesco Orlandi, Makoto Nishio, Ticiana Leal, David R. Spigel, Simonetta Mocci and Raffaele Califano and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer Research.
In The Last Decade
See Phan
22 papers receiving 1.8k citations
Hit Papers
Peers
See Phan
Paul Conkling United States
Atsushi Horiike Japan
Panos Fidias United States
Craig H. Reynolds United States
Saiama N. Waqar United States
Henrik Roed Denmark
Walter L. Vervenne Netherlands
G. Veerman Netherlands
Toshiyuki Kozuki Japan
Annetta Krebs United States
Citations per year, relative to See Phan See Phan (= 1×)
peers
Paul Conkling
Countries citing papers authored by See Phan
Since
Specialization
Citations
This map shows the geographic impact of See Phan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by See Phan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites See Phan more than expected).
Fields of papers citing papers by See Phan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by See Phan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by See Phan. The network helps show where See Phan may publish in the future.
Co-authorship network of co-authors of See Phan
This figure shows the co-authorship network connecting the top 25 collaborators of See Phan. A scholar is included among the top collaborators of See Phan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with See Phan. See Phan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kim, Edward S., Vamsidhar Velcheti, Tarek Mekhail, et al.. (2022). Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nature Medicine. 28(5). 939–945.
2.
Liu, Stephen V., Martin Reck, Aaron S. Mansfield, et al.. (2021). Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). Journal of Clinical Oncology. 39(6). 619–630.
3.
Jassem, Jacek, Filippo de Marinis, Giuseppe Giaccone, et al.. (2021). Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC. Journal of Thoracic Oncology. 16(11). 1872–1882.
4.
Nishio, Makoto, Fabrice Barlési, Howard West, et al.. (2020). Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial.. Journal of Thoracic Oncology.
5.
Nishio, Makoto, Fabrice Barlési, Howard West, et al.. (2020). Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. Journal of Thoracic Oncology. 16(4). 653–664.
6.
Marinis, Filippo de, Giuseppe Giaccone, Roy S. Herbst, et al.. (2020). Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC.. Journal of Clinical Oncology. 38(15_suppl). 9594–9594.
7.
Jassem, Jacek, Roy S. Herbst, Filippo de Marinis, et al.. (2020). IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 38(15_suppl). e21623–e21623.
8.
Horn, Leora, Stephen V. Liu, Aaron S. Mansfield, et al.. (2020). Abstract CT220: IMpower133: Updated OS and exploratory analyses of first-line (1L) atezolizumab (atezo) + carboplatin (C) + etoposide (E) in extensive-stage SCLC (ES-SCLC). Cancer Research. 80(16_Supplement). CT220–CT220.
9.
Socinski, Mark A., Sarah Paul, Cindy Yun, et al.. (2019). Abstract CT194: Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (pts) with low circulating tumor DNA (ctDNA) in B-F1RST—a Phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLC. Cancer Research. 79(13_Supplement). CT194–CT194.
10.
Socinski, Mark A., Sarah Paul, Cindy Yun, et al.. (2019). Abstract CT194: Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (pts) with low circulating tumor DNA (ctDNA) in B-F1RST—a Phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLC. Clinical Trials. CT194–CT194.
11.
Cruickshanks, Nichola, Ying Zhang, Myron Gibert, et al.. (2018). Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma. Clinical Cancer Research. 25(2). 663–673.
12.
Spigel, David R., Martin J. Edelman, Kenneth J. O’Byrne, et al.. (2017). Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung. Journal of Clinical Oncology. 35(4). 412–420.
13.
Spigel, David R., Martin J. Edelman, Kenneth J. O’Byrne, et al.. (2017). Results from the phase iii randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage iiib or iv non–small-cell lung cancer: METLung. LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas).
14.
Owen, Dwight H., Paul A. Bunn, Bruce E. Johnson, et al.. (2017). A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 35(15_suppl). TPS8580–TPS8580.
15.
Socinski, Mark A., Shaker R. Dakhil, Joseph L. Leach, et al.. (2016). PS01.54: Evaluation of Novel Blood-Based Biomarkers with Atezolizumab Monotherapy in 1L Advanced or Metastatic NSCLC (B-F1RST). Journal of Thoracic Oncology. 11(11). S303–S304.
16.
Shah, Manish A., Yung‐Jue Bang, Florian Lordick, et al.. (2016). Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma. JAMA Oncology. 3(5). 620–620.
17.
Hirsch, Fred R., Ramaswamy Govindan, Zanete Zvirbule, et al.. (2016). Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 18(1). 43–49.
18.
Wakelee, Heather A., Zanete Zvirbule, Filippo de Braud, et al.. (2016). Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 18(1). 50–59.
19.
Mehta, Minesh P., William R. Shapiro, See Phan, et al.. (2008). Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Non–Small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III Trial. International Journal of Radiation Oncology*Biology*Physics. 73(4). 1069–1076.
20.
Mañon, R., Susanta Hui, Prakash Chinnaiyan, et al.. (2004). The Impact of Mid-Treatment MRI on Defining Boost Volumes in the Radiation Treatment of Glioblastoma Multiforme. Technology in Cancer Research & Treatment. 3(3). 303–307.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Paul Conkling Breakdown of academic impact, for papers by Atsushi Horiike Breakdown of academic impact, for papers by Panos Fidias Breakdown of academic impact, for papers by Craig H. Reynolds Breakdown of academic impact, for papers by Saiama N. Waqar Breakdown of academic impact, for papers by Henrik Roed Breakdown of academic impact, for papers by Walter L. Vervenne Breakdown of academic impact, for papers by G. Veerman Breakdown of academic impact, for papers by Toshiyuki Kozuki Breakdown of academic impact, for papers by Annetta Krebs